ACM
EBS icon

Aster Capital Management’s Emergent Biosolutions EBS Stock Holding History

Aster Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,337
Closed -$74.5K – 954
2026
Q1 		$74.5K Buy
+15,337
New +$159K 0.02% 370
2025
Q1 		– Sell
-30,606
Closed -$293K – 1355
2024
Q4 		$293K Hold
30,606
– – 0.11% 229
2024
Q3 		$256K Buy
+30,606
New +$278K 0.06% 276

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Aster Capital Management's EBS Position: Q2 2026 in Review

Aster Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2026, closing a stake of 15,337 shares — an estimated $74.5K sold.

Aster Capital Management first reported a position in EBS in Q3 2024 and held it in 3 quarters. The position peaked at $293K in Q4 2024. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Aster Capital Management reported no remaining Emergent Biosolutions position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 15,337 Emergent Biosolutions shares in Q2 2026, an estimated $74.5K.
  • Aster Capital Management first reported a position in Emergent Biosolutions in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's Emergent Biosolutions position peaked at $293K in Q4 2024.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.